According to a new report, published by KBV research, The Global Legionella Testing Market size is expected to reach $578.9 million by 2030, rising at a market growth of 9.6% CAGR during the forecast period.
The Polymerase Chain Reaction (PCR) segment led the Global Legionella Testing Market, by Type in 2022; thereby, achieving a market value of $234.7 million by 2030. The sensitivity, accuracy, and precision of the results produced by polymerase chain reaction make it the preferred method for testing samples. In the pharmaceutical and life science sectors, polymerase chain reaction (PCR) is crucial in developing assays, culture media, and test kits and solutions. The increasing application of these PCR methods to diagnosing diseases drives market expansion.
The Clinical Laboratories segment is growing at a CAGR of 9.2 % during the forecast period. The consistent availability of funds for medical research purposes has resulted from the constant increase in government funding in the healthcare sector of developing nations, which in turn drives clinical laboratories. Legionella testing is also significantly impacted by the increasing private financing in the pharma industry in developed countries, which has spurred the development of diagnostic technologies.
The North America region dominated the Global Legionella Testing Market, by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $209 million by 2030. The Europe region is anticipated to grow at a CAGR of 9.4% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 10.4% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/legionella-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of QuidelOrtho Corporation, Abbott Laboratories, Merck KGaA, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton Dickinson and Company, BioMerieux S.A., IDEXX Laboratories, Inc., Eurofins Scientific SE and Qiagen N.V.
By Type
By End-User
By Geography
Companies Profiled
Unique Offerings 
